Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

Presentation

Predictors and Outcomes of Staged vs One-Time Revascularization in Multivessel CAD

November 20, 2018

Presentation AHA 2018

Ticagrelor vs Aspirin in Patients undergoing Coronary-Artery Bypass Grafting

Presenter: Heribert Schunkert

November 14, 2018

Presentation

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

July 11, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

Presenter: Allen Jeremias

May 06, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Presenter: Rasha Al-Lamee

May 05, 2018

Presentation

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

April 17, 2018

Presentation Fellows 2018

ACS Pharmacology for the Interventionalist

Presenter: Duane S. Pinto, Gregg W. Stone

April 13, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

Presentation ACC 2018

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Presenter: Tracy Wang

March 12, 2018

Presentation ACC 2018

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Presenter: Philip Devereaux

March 12, 2018

Presentation ACC 2018

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Presenter: Francesco Franchi

March 11, 2018

Presentation JIM 2018

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Presenter: Ferdinando Varbella

February 23, 2018

Presentation JIM 2018

Vascular Complications

Presenter: Bernhard Reimers

February 23, 2018

Presentation JIM 2018

Case: Immediate PCI + downstream clopidogrel

Presenter: Giuseppe Tarantini

February 23, 2018

Presentation JIM 2018

Clinical Case: Management of Long-Term DAPT

Presenter: Ugo Limbruno

February 23, 2018

Advertisement

Predictors and Outcomes of Staged vs One-Time Revascularization in Multivessel CAD

Ticagrelor vs Aspirin in Patients undergoing Coronary-Artery Bypass Grafting

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

ACS Pharmacology for the Interventionalist

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Case: Immediately after PCI and BAV the patient was given aspirin 250 mg iv and Plavix 300 mg

Vascular Complications

Case: Immediate PCI + downstream clopidogrel

Clinical Case: Management of Long-Term DAPT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content